The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Enabling efficient patient discharge with a mindset, toolset, and skillset framework.
 
Corey Russell
No Relationships to Disclose
 
Kaycee Wilson
No Relationships to Disclose
 
Amin Majid Alousi
Honoraria - Genentech; generon; kadmon; Prolacta Bioscience
Consulting or Advisory Role - Incyte; Sanofi
 
Catherine Delanoix
Employment - MD Anderson Cancer Center
 
Jennifer Freeman
No Relationships to Disclose
 
Zandra R. Rivera
No Relationships to Disclose
 
Nicole Brunelle
Honoraria - Incyte (I); Sanofi (I)
Consulting or Advisory Role - Genentech (I); Generon (I); Kadmon (I); Prolacta Bioscience (I)
 
Sascha Seurattan-Smith
No Relationships to Disclose
 
Alison M. Gulbis
No Relationships to Disclose
 
Whitney Wallis
No Relationships to Disclose
 
Marina C. George
Consulting or Advisory Role - Daiichi Sankyo (I); Marvin Health (I)
Travel, Accommodations, Expenses - Melinta Therapeutics
 
Christopher Flowers
Stock and Other Ownership Interests - Foresight Diagnostics; N Power
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Curio Science; Denovo Biopharma; Epizyme; Foresight Diagnostics; Genentech/Roche; Genmab; Gilead Sciences; MorphoSys; Pharmacyclics/Janssen
Research Funding - 4D Pharma (Inst); Abbvie (Inst); Acerta Pharma (Inst); Adaptimmune (Inst); Alimera Sciences (Inst); Amgen (Inst); Bayer (Inst); Celgene (Inst); Cellectis (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Guardant Health (Inst); Iovance Biotherapeutics (Inst); Janssen Oncology (Inst); Kite/Gilead (Inst); Millennium (Inst); MorphoSys (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Takeda (Inst); TG Therapeutics (Inst); Xencor (Inst); ZIOPHARM Oncology (Inst)
 
William G. Wierda
Consulting or Advisory Role - Sanofi
Research Funding - Abbvie; Acerta Pharma; Bristol-Myers Squibb; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Kite, a Gilead company; Loxo; MDACC Cancer Center Support Grant; NIH/NCI award number CA016672; Novartis; Numab; Nurix; Oncternal Therapeutics, Inc; Pharmacyclics; Xencor
 
Elizabeth J. Shpall
Honoraria - Bayer
Consulting or Advisory Role - Adaptimmune; AXIO Research; Celaid Therapeutics; Fibrobiologics; Navan; NY Blood Center
Patents, Royalties, Other Intellectual Property - Affimed Therapeutics; Syena; Takeda
Travel, Accommodations, Expenses - Magenta Therapeutics; Novartis